IP Library Granted Patent US 12,180,513
Granted Patent B2
US 12,180,513 · App. 18/498,879 · Granted Dec 31, 2024

Method for large-scale production of lentivirus by using GMP-level serum-free suspension cells

Inventors: Yi Hong (Shanghai, CN); Ting Yan (Shanghai, CN); Jiangguo Ying (Shanghai, CN); Haojie Zhang (Shanghai, CN); Luyi Zhang (Shanghai, CN); Li Zhang (Shanghai, CN)
Assignee: Shanghai AbelZeta Ltd.
C12N7/00C12N15/86C12N2740/15043C12N2740/15051C12N2740/16043C12N2740/16051
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,180,513
App. No.
18/498,879
Granted
Dec 31, 2024
Kind
B2
Abstract

Provided is a method for large-scale production of lentivirus by using GMP-level serum-free suspension cells. Said method comprises the following steps: (a) providing a seed solution of packaged cells; (b) inoculating the seed solution in a first culture solution; (c) carrying out subculture of the packaged cells; (d) starting a liquid change operation when a liquid change trigger condition is met; (e) repeating steps (c) and (d) 1, 2 or 3 times; (f) starting a transfection operation when a transfection trigger condition is met; (g) optionally performing liquid change after transfection; (h) cultivating the transfected packaged cells; (i) starting harvesting and liquid change operations when a liquid change trigger condition is met; (j) repeating steps (h) and (i) 1, 2 or 3 times; (k) combining each of the recovered liquids; and (l) performing a purifying treatment. The culture solution used in each step is a serum-free cell culture solution.

Claims (43)

1. A method for producing lentiviruses using cells in serum-free suspension culture, the method comprising:

(a) providing packaging cells that grow in suspension;

(b) inoculating the packaging cells in a first culture medium, wherein the first culture medium is a serum-free cell culture medium;

(c) culturing the inoculated packaging cells, at conditions set at a temperature of 30-38° C., a dissolved oxygen concentration of 35-55%, a CO 2 concentration of 2-10% and a pH of 6.9-7.4, and controlling dissolved oxygen and/or CO 2 concentrations to maintain the pH between 6.9-7.4;

(d) preforming a first liquid change when liquid change trigger conditions are met,

wherein the liquid change trigger conditions comprise:

(s1) the pH is ≤6.9; and

(s2) a culture time is ≥72 hours;

(e) repeating steps (c) and (d) n times, wherein n is 0, 1, 2, or 3;

(f) performing transfection;

(g) optionally carrying out post-transfection liquid change;

(h) culturing the transfected packaging cells, at culture conditions set at a temperature of 30-37° C., a dissolved oxygen concentration of 35-55%, a CO 2 concentration of 2-10% and a pH of 6.9-7.4, and controlling dissolved oxygen and/or CO 2 concentrations to maintain the pH between 6.9-7.4.

2. The method of claim 1 , wherein in step (b), the packaging cells are inoculated at an inoculation density ranging from about 1×10 6 cells/ml to about 5×10 6 cells/ml.

3. The method of claim 1 , wherein in step (b), the first culture medium has a volume ranging from about 3 liters to about 100 liters.

4. The method of claim 1 , wherein in step (d), the pH is ≤7.0.

5. The method of claim 1 , wherein in step (d), the pH is ≤7.05.

6. The method of claim 1 , wherein in step (c) and/or (h), the culture is performed under a shaking condition.

7. The method of claim 1 , wherein in step (c) and/or (h), the pH is maintained between 7.0 and 7.35.

8. The method of claim 1 , wherein the total time of steps (c), (d) and (e) is 72-216 hours.

9. The method of claim 1 , wherein the method produces 1×10 12 transducing units (TU) lentiviruses.

10. The method of claim 1 , wherein the packaging cells are human embryonic kidney epithelial cells.

11. The method of claim 1 , wherein in step (d), the first liquid change comprises:

harvesting a supernatant of the culture, wherein the culture before harvesting the supernatant has a volume of Vq1, wherein the culture after harvesting the supernatant has a volume of Vh1, and wherein the ratio of Vq1/Vh1 is 3-15; and

adding a second culture medium to the culture, wherein the second culture medium is a serum-free cell culture medium.

12. The method of claim 11 , wherein the ratio of Vq1/Vh1 is 5-10.

13. The method of claim 1 , wherein in step (f), the transfection is performed when transfection trigger conditions are met,

wherein the transfection trigger conditions comprise:

(t1) the total number of cells is 0.05-2×10 11 cells;

(t2) the cell density is 0.5-5×10 6 cells/mi;

(t3) the cell viability rate is ≥90%; and

(t4) the total culture time is ≥72 hours.

14. The method of claim 1 , further comprising:

(i) starting a second liquid change when liquid change trigger conditions are met,

wherein the liquid change trigger conditions comprise:

(s1) the pH is 56.9; and

(s2) a culture time is 272 hours; and

(j) repeating steps (h) and (i) m times, wherein m is 0, 1, 2, or 3.

15. The method of claim 14 , wherein in step (i), the pH is ≤7.0.

16. The method of claim 14 , wherein in step (i), the pH is ≤7.05.

17. The method of claim 14 , wherein in step (i), the second liquid change comprises: harvesting a supernatant of the culture, wherein the culture before harvesting the supernatant has a volume of Vq2, wherein the culture after harvesting the supernatant has a volume of Vh2, and wherein the ratio of Vq2/Vh2 is 3-15.

18. The method of claim 17 , wherein the ratio of Vq2/Vh2 is 5-10.

19. The method of claim 1 , wherein in step (f), the transfection comprises: mixing one or more plasmids with a transfection reagent to form a mixture, and adding the mixture to the culture.

20. The method of claim 19 , wherein the one or more plasmids comprise three plasmids or four plasmids.

Assignments (4)
CORRECTIVE ASSIGNMENT TO CORRECT THE RECEIVING PARTY DATA PREVIOUSLY RECORDED AT REEL: 67128 FRAME: 44. ASSIGNOR(S) HEREBY CONFIRMS THE CHANGE OF NAME. Recorded May 7, 2024
From: SHANGHAI CELLULAR BIOPHARMACEUTICAL GROUP LTD.
To: SHANGHAI ABELZETA LTD.
Reel/Frame 067334/0083 →
CHANGE OF NAME Recorded Apr 16, 2024
From: SHANGHAI CELLULAR BIOPHARMACEUTICAL GROUP LTD.
To: SHANGHAI ABELZETA LTD.
Reel/Frame 067128/0044 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 31, 2023
From: HONG, YI; YAN, TING; YING, JIANGGUO; ZHANG, HAOJIE; ZHANG, LUYI; ZHANG, LI
To: CELLULAR BIOMEDICINE GROUP HK LTD
Reel/Frame 065409/0240 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 31, 2023
From: CELLULAR BIOMEDICINE GROUP HK LTD.
To: SHANGHAI CELLULAR BIOPHARMACEUTICAL GROUP LTD.
Reel/Frame 065409/0339 →
Priority Claims (1)
CN 201810273392.7 · Mar 29, 2018 · national
Continuity (2)
Continuation 17041578
Related Publication 20240060053A1 · Feb 22, 2024